Skip to main content

Table 2 Laboratory investigation in Case 2

From: Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Laboratory examinations

Complete blood cell count

γGTP

547

U/L

Viral markers

WBC

5510

u/L

ChE

219

U/L

HBs antigen

(–)

RBC

389

104 u/L

Na

139

mEg/L

HCV antibody

(–)

Hg

12.8

g/dL

K

3.6

mEg/L

Liver function

Ht

39.5

%

Cl

103

mEg/L

ICG-R

26.6%

Plt

12.6

104 u/L

TP

7.6

g/dL

Child–Pugh score

6

Blood coagulation test

Alb

3.9

g/dL

Child–Pugh grade

A

PT (%)

90.8

%

BUN

17.3

mg/dL

ALBI score

-1.92

PT-INR

1.05

 

Cr

0.61

mg/dL

mALBI grade

2b

Blood chemistry

CRP

0.64

mg/dL

  

T-Bil

3.7

mg/dL

HbA1c

6

%

  

AST

254

U/L

Tumor markers

  

ALT

230

U/L

AFP

570.6

ng/mL

  

LDH

447

U/L

DCP

65,143

mAU/mL

  
  1. γGTP: γ-glutamil transpeptidase, AFP: alpha-fetoprotein, Alb: albumin, ALBI: albumin–bilirubin, ALP: alkaline phosphatase, ALT: alanine aminotransferase, AST: aspatate aminotransferase, BUN: blood–urea–nitrogen, ChE: cholinesterase, Cr: creatinine, CRP: C-reactive protein, DCP: des-gamma carboxyprothrombin, Hb: hemoglobin, HbA1c: hemoglobin A1c, HBs antigen: hepatitis B surface antigen, HCV antibody: hepatitis C virus antibody, Ht: hematocrit, ICG-R: indocyanine green retention, LHD: lactate dehydrogenase, Plt: platelets, PT: prothrombin time, PT-INR: international normalized ratio of prothrombin time, RBC: red bllod cells, T-Bil: total bilirubin, TP: total protein, WBC: white blood cells